RxDoctor Payments Data

Jonathon Sossamon

Family Medicine · Deridder, LANPI 1114304375

Payments from drug & device makers

$440in general payments, 2019–2025

Across 26 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$199
  • Amgen$34
  • Abbott$30
  • Lilly USA, LLC$29
  • Boehringer Ingelheim$27
  • Lundbeck LLC$21
  • plus $100 from 6 others

What the payments were for

  • Food & beverage$440100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$440 in reported general payments places this provider in the 40th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$202,360
Medicare patients
395
Services billed
2,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$64,849
TrulicityDulaglutide20$40,251
FarxigaDapagliflozin Propanediol29$35,434
OzempicSemaglutide31$26,730
JanuviaSitagliptin Phosphate22$20,889
MounjaroTirzepatide13$19,773
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$14,389
Combivent RespimatIpratropium/Albuterol Sulfate18$10,047
JardianceEmpagliflozin11$9,214
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,801
Breo ElliptaFluticasone/Vilanterol12$4,874
Gabapentin279$4,682
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,389
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,885
Atorvastatin Calcium384$3,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$29$60,02433 claims
Novo NordiskOzempic$199$26,73031 claims
Boehringer IngelheimCombivent Respimat, Jardiance$27$19,26029 claims
AbbVieSynthroid$18$2,30826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Deridder

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →